.Pharmacolibrary.Drugs.R_RespiratorySystem.R05D_CoughSuppressantsExclCombinationsWithExpectorant.R05DB12_BibenzoniumBromide.BibenzoniumBromide .Pharmacolibrary.Drugs.R_RespiratorySystem.R05D_CoughSuppressantsExclCombinationsWithExpectorant.R05DB12_BibenzoniumBromide.BibenzoniumBromide| name: | BibenzoniumBromide |
| ATC code: | R05DB12 | route: | oral |
| n-compartments | 1 |
Bibenzonium bromide is a quaternary ammonium compound classified as an antitussive, used for the treatment of cough. It acts as a peripheral antitussive agent, likely by suppressing the cough reflex through local action in the respiratory tract. It is not widely approved or currently used in most countries.
No published pharmacokinetic data for bibenzonium bromide in humans was found. The following parameters are rough estimates based on related quaternary ammonium antitussives.
Tytgat, GN (2007). Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 67(9) 1343–1357. DOI:10.2165/00003495-200767090-00007 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17547475
Mozaffari, S, et al., & Abdollahi, M (2018). Methylnaltrexone bromide for the treatment of opioid-induced constipation. Expert opinion on pharmacotherapy 19(10) 1127–1135. DOI:10.1080/14656566.2018.1491549 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29979903
Guirguis-Blake, JM, et al., & Whitlock, EP (2016). Screening for Chronic Obstructive Pulmonary Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 315(13) 1378–1393. DOI:10.1001/jama.2016.2654 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27046366